Aberrant pre-mRNA processing in cancer

被引：2

作者：

Biswas, Jeetayu ^{[1
,2
]}

Boussi, Leora ^{[2
]}

Stein, Eytan ^{[2
]}

Abdel-Wahab, Omar ^{[1
,2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10065 USA

来源：

JOURNAL OF EXPERIMENTAL MEDICINE | 2024年 / 221卷 / 11期

基金：

美国国家卫生研究院;

关键词：

SPLICING FACTOR SF3B1; 1ST-IN-HUMAN PHASE-I; MYELODYSPLASTIC SYNDROMES; DRIVER MUTATIONS; INTRON RETENTION; GENE-EXPRESSION; UVEAL MELANOMA; INHIBITOR; LEUKEMIA; MODULATION;

D O I：

10.1084/jem.20230891

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This review describes the current state of understanding of how RNA processing is dysregulated in cancer (including alterations in RNA splicing, capping, polyadenylation, and decay) and how this knowledge is being harnessed for therapeutic intent. Dysregulation of the flow of information from genomic DNA to RNA to protein occurs within all cancer types. In this review, we described the current state of understanding of how RNA processing is dysregulated in cancer with a focus on mutations in the RNA splicing factor machinery that are highly prevalent in hematologic malignancies. We discuss the downstream effects of these mutations highlighting both individual genes as well as common pathways that they perturb. We highlight examples of how alterations in RNA processing have been harnessed for therapeutic intent as well as to promote the selective toxicity of cancer cells.

引用

页数：14

共 165 条

[31] Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia [J].

Cortes, Jorge ;

Kantarjian, Hagop ;

Ball, Edward D. ;

DiPersio, John ;

Kolitz, Jonathan E. ;

Fernandez, Hugo F. ;

Goodman, Mark ;

Borthakur, Gautam ;

Baer, Maria R. ;

Wetzler, Meir .

CANCER, 2012, 118 (02) :418-427

[32] Mutations affecting mRNAsplicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes [J].

Damm, Frederik ;

Kosmider, Olivier ;

Gelsi-Boyer, Veronique ;

Renneville, Aline ;

Carbuccia, Nadine ;

Hidalgo-Curtis, Claire ;

Della Valle, Veronique ;

Couronne, Lucile ;

Scourzic, Laurianne ;

Chesnais, Virginie ;

Guerci-Bresler, Agnes ;

Slama, Bohrane ;

Beyne-Rauzy, Odile ;

Schmidt-Tanguy, Aline ;

Stamatoullas-Bastard, Aspasia ;

Dreyfus, Francois ;

Prebet, Thomas ;

de Botton, Stephane ;

Vey, Norbert ;

Morgan, Michael A. ;

Cross, Nicholas C. P. ;

Preudhomme, Claude ;

Birnbaum, Daniel ;

Bernard, Olivier A. ;

Fontenay, Michaela .

BLOOD, 2012, 119 (14) :3211-3218

[33] Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth [J].

Dewaele, Michael ;

Tabaglio, Tommaso ;

Willekens, Karen ;

Bezzi, Marco ;

Teo, Shun Xie ;

Low, Diana H. P. ;

Koh, Cheryl M. ;

Rambow, Florian ;

Fiers, Mark ;

Rogiers, Aljosja ;

Radaelli, Enrico ;

Al-Haddawi, Muthafar ;

Tan, Soo Yong ;

Hermans, Els ;

Amant, Frederic ;

Yan, Hualong ;

Lakshmanan, Manikandan ;

Koumar, Ratnacaram Chandrahas ;

Lim, Soon Thye ;

Derheimer, Frederick A. ;

Campbell, Robert M. ;

Bonday, Zahid ;

Tergaonkar, Vinay ;

Shackleton, Mark ;

Blattner, Christine ;

Marine, Jean-Christophe ;

Guccione, Ernesto .

JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (01) :68-84

[34] Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes [J].

Dolatshad, H. ;

Pellagatti, A. ;

Liberante, F. G. ;

Llorian, M. ;

Repapi, E. ;

Steeples, V. ;

Roy, S. ;

Scifo, L. ;

Armstrong, R. N. ;

Shaw, J. ;

Yip, B. H. ;

Killick, S. ;

Kusec, R. ;

Taylor, S. ;

Mills, K. I. ;

Savage, K. I. ;

Smith, C. W. J. ;

Boultwood, J. .

LEUKEMIA, 2016, 30 (12) :2322-2331

[35]

Dolatshad H, 2015, LEUKEMIA, V29, P1092, DOI [10.1038/leu.2014.331, 10.1038/leu.2015.178]

[36] Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820 [J].

Du, Xinlin ;

Volkov, Oleg A. ;

Czerwinski, Robert M. ;

Tan, HuiLing ;

Huerta, Carlos ;

Morton, Emily R. ;

Rizzi, Jim P. ;

Wehn, Paul M. ;

Xu, Rui ;

Nijhawan, Deepak ;

Wallace, Eli M. .

STRUCTURE, 2019, 27 (11) :1625-+

[37] CDK12 regulates DNA repair genes by suppressing intronic polyadenylation [J].

Dubbury, Sara J. ;

Boutz, Paul L. ;

Sharp, Phillip A. .

NATURE, 2018, 564 (7734) :141-+

[38] Cancer immunoediting: from immunosurveillance to tumor escape [J].

Dunn, GP ;

Bruce, AT ;

Ikeda, H ;

Old, LJ ;

Schreiber, RD .

NATURE IMMUNOLOGY, 2002, 3 (11) :991-998

[39] RNA splicing factors as oncoproteins and tumour suppressors [J].

Dvinge, Heidi ;

Kim, Eunhee ;

Abdel-Wahab, Omar ;

Bradley, Robert K. .

NATURE REVIEWS CANCER, 2016, 16 (07) :413-430

[40] Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors [J].

El-Khoueiry, Anthony B. B. ;

Clarke, James ;

Neff, Tobias ;

Crossman, Tim ;

Ratia, Nirav ;

Rathi, Chetan ;

Noto, Paul ;

Tarkar, Aarti ;

Garrido-Laguna, Ignacio ;

Calvo, Emiliano ;

Rodon, Jordi ;

Tran, Ben ;

O'Dwyer, Peter J. J. ;

Cuker, Adam ;

Razak, Albiruni R. Abdul R. .

BRITISH JOURNAL OF CANCER, 2023, 129 (02) :309-317

← 1 2 3 4 5 6 7 8 9 10 →